Loved their revenue growth (which included only 16 days of Cannimed) should accelerate even more in the 4th quarter ending 6/30/2018 and further accelerate for the fiscal year 7/1/2018-6/30/2019.Operating costs continue to be a problem ($39,371 million), however some are attributable to expansion and acquisition costs ( ie: legal fees, travel and all other related costs for growth). These costs should decrease substantially next year. With much higher sales and lower costs going forward , the bottom line should improve dramatically next year.
From the filing today, below is one example of one time expenses related to growth that will disappear in the fiscal year 7/1/2018-2019 (there are others-see the filing on Seder:
"The Company incurred legal, consulting and advisory fees relating to business acquisitions and due diligence activities as part of its aggressive domestic and international expansion strategy, with primarily $5.5 million attributable to the Cannimed Offe
Market Data 
Markets 
AI
